Cart
sales@molnova.com
MK2-IN-28
CAS No. 1355617-50-3
MK2-IN-28( —— )
Catalog No. M11456 CAS No. 1355617-50-3
A potent and selective, non-ATP competitive, allosteric MAPKAPK2/3 (MK2/3) inhibitor with IC50 of 8 nM for MK2, hTNFα EC50 of 0.31 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMK2-IN-28
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective, non-ATP competitive, allosteric MAPKAPK2/3 (MK2/3) inhibitor with IC50 of 8 nM for MK2, hTNFα EC50 of 0.31 uM.
-
DescriptionA potent and selective, non-ATP competitive, allosteric MAPKAPK2/3 (MK2/3) inhibitor with IC50 of 8 nM for MK2, hTNFα EC50 of 0.31 uM; inhibits both MK2 and MK3, and has no or little effect on the other kinases; ameliorates glucose homeostasis by suppressing excessive HGP and enhancing insulin signaling in obese mice.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetMAPKAPK2 (MK2)
-
RecptorMAPKAPK2 (MK2)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1355617-50-3
-
Formula Weight569.665
-
Molecular FormulaC35H31N5O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name5-(4-cyanophenyl)-N-(2-(4-methoxypyridin-3-yl)benzyl)-N-(4-(piperazin-1-yl)phenyl)furan-2-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Huang X, et al. Bioorg Med Chem Lett. 2012 Jan 1;22(1):65-70.
2. Ozcan L, et al. Diabetes. 2015 Oct;64(10):3396-405.
molnova catalog
related products
-
PF-3644022
PF-3644022 is a potent and selective, freely reversible, ATP-competitive inhibitor of MAPKAP2 (MK2) with Ki of 3 nM.
-
MK2 inhibitor III
A potent, cell-permeable inhibitor of MK2 with IC50 of 8.5 nM; less potently blocks MK3 and MK5 (IC50s=210 and 81 nM, respectively).
-
MK2-IN-28
A potent and selective, non-ATP competitive, allosteric MAPKAPK2/3 (MK2/3) inhibitor with IC50 of 8 nM for MK2, hTNFα EC50 of 0.31 uM.
